HZNP - Horizon Therapeutics Public Limited Company
30.00 +0.38 (1.28%)
After hours: 5:51PM EDT
| Previous Close | 29.35 |
| Open | 29.30 |
| Bid | 26.25 x 800 |
| Ask | 31.00 x 1100 |
| Day's Range | 28.90 - 30.09 |
| 52 Week Range | 22.69 - 39.10 |
| Volume | 1,593,664 |
| Avg. Volume | 1,689,727 |
| Market Cap | 5.632B |
| Beta (5Y Monthly) | 0.94 |
| PE Ratio (TTM) | 10.21 |
| EPS (TTM) | 2.90 |
| Earnings Date | Feb 25, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44.70 |
- Business Wire
TEPEZZA™ (teprotumumab-trbw) Significantly Reduces Proptosis (Eye Bulging), a Key Marker of Thyroid Eye Disease, Across Patient Subtypes
Horizon Therapeutics announces new pooled efficacy data for TEPEZZA (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED).
- Investor's Business Daily
Why These 7 Pharma Stocks Are Outplaying 90% Of The Stock Market
Pharmaceutical stocks dipped by a double-digit percentage in the first three months of 2020, trailing their biotech brethren. Still, there are standout companies in the industry group.
- Business Wire
Horizon Therapeutics plc Donates $1.5 Million to COVID-19 Response Efforts in Illinois and Other Impacted U.S. and Global Communities
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it, in partnership with Illinois Governor JB Pritzker, has provided $500,000 to the Illinois COVID-19 Response Fund and $500,000 to the Illinois Biotechnology Innovation Organization (iBIO) Institute’s COVID-19 Response Fund.
- Insider Monkey
Should You Buy Horizon Pharma Public Limited Company (HZNP)?
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- Simply Wall St.
Should You Worry About Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) CEO Salary Level?
Tim Walbert has been the CEO of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) since 2008. This analysis...
- Investopedia
Top Pharmaceutical Stocks for Q2 2020
The pharmaceutical industry is part of the larger health care sector. Companies in the pharmaceutical industry research, develop, manufacture, and market medicines and drugs. The best-known pharmaceutical companies are, among others, Eli Lilly & Co.
- Business Wire
Horizon Therapeutics plc Launches the Down and Out Kidney Campaign to Call Attention to the Prevalence and Impact of Gout in Chronic Kidney Disease
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of Down and Out Kidney, a campaign to highlight the damaging effects associated with the accumulation of uric acid and gout in people with chronic kidney disease (CKD).
- Business Wire
Horizon and Willis Tower Elevate the Need for Rare Disease Innovation on Rare Disease Day
Horizon Therapeutics (Nasdaq: HZNP) and Willis Towers Watson (Nasdaq: WLTW) are partnering with Willis Tower to light the antennas of the Willis Tower on Feb. 29 in recognition of Rare Disease Day and to raise awareness of the crucial need to identify new medicines for the 30 million people living with rare diseases in the United States. The antennas will be illuminated in the colors of the rising sun (Horizon’s corporate colors) elevating Horizon’s commitment to partnering with the community to raise awareness and bring forward new medicines for rare diseases.
- Business Wire
Horizon Therapeutics plc Partners with EveryLife Foundation to Establish $1 Million #RAREis Scholarship for Adults with Rare Diseases
Horizon Therapeutics plc (Nasdaq: HZNP) today announced a $1 million commitment over five years to establish the RAREis scholarship, a program that will be made available by the EveryLife Foundation for Rare Diseases. The RAREis scholarship will support the pursuit of life enrichment activities for adults living with rare diseases for a variety of educational pursuits, including educational courses, travel stipends for rare disease conferences and obtaining two-and four-year degrees.
- Business Wire
Horizon Therapeutics plc Named One of the Best Workplaces in Ireland
Horizon Therapeutics plc (Nasdaq: NZNP) today announced that it has been recognized as one of the 2020 Best Workplaces in Ireland, ranking 13th in the small company category. This is the first year that Horizon has been named to the Ireland list.
- Thomson Reuters StreetEvents
Edited Transcript of HZNP earnings conference call or presentation 26-Feb-20 1:00pm GMT
Q4 2019 Horizon Therapeutics PLC Earnings Call
- Business Wire
Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2019 Financial Results; Announces Full-Year 2020 Guidance
Horizon Therapeutics plc (Nasdaq: HZNP) today announced its fourth-quarter and full-year 2019 financial results and provided its full-year 2020 net sales and adjusted EBITDA guidance.
- Business Wire
Horizon Therapeutics plc to Present at the Cowen and Company 40th Annual Health Care Conference
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in March:
- Business Wire
Horizon Therapeutics plc Announces U.S. FDA Approval of New Dosage Form for PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI® (cysteamine bitartrate) delayed-release oral granules in packets for adults and children one year of age and older living with nephropathic cystinosis. This new dosage form provides another option for people living with cystinosis, in addition to the currently available PROCYSBI capsules.
- Business Wire
Uplifting Athletes Announces Horizon Therapeutics plc as Exclusive Sponsor to Help Tackle Rare Disease at the National Football League (NFL) Scouting Combine
Horizon Therapeutics plc (Nasdaq: HZNP) and Uplifting Athletes today announced a new partnership for the 2020 Reps for Rare Disease campaign, which offers an opportunity for NFL Draft prospects to give back and support the rare disease community. Participants who team up with Uplifting Athletes will dedicate their performance in one event – bench press, vertical jump or broad jump – at the NFL Scouting Combine or their school’s official pro day, to raising funds for rare disease research and awareness initiatives.
- Zacks
Allergan (AGN) to Report Q4 Earnings: What's in the Cards?
Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q4 as loss of exclusivity of several products hurts sales.
- Zacks
What's in Store for Innoviva (INVA) This Earnings Season?
Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter, which is partially offset by lower royalties from Relvar/Breo Ellipta.
- Business Wire
Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2019 Financial Results and Host Webcast on Feb. 26, 2020
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its fourth-quarter and full-year 2019 financial results will be released on Wednesday, Feb. 26, 2020. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
- Zacks
Why the Earnings Surprise Streak Could Continue for Horizon Therapeutics (HZNP)
Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks
REGN vs. HZNP: Which Stock Is the Better Value Option?
REGN vs. HZNP: Which Stock Is the Better Value Option?
- Zacks
Horizon Therapeutics Gets FDA Approval for Eye Drug Tepezza
Horizon Therapeutics' (HZNP) Tepezza becomes the first FDA-approved therapy for treating thyroid eye disease, a rare, autoimmune disease. Stock up.
- Zacks
Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon
A low-key week for the biotech sector with a few pipeline and regulatory updates.
